September 8, 2016

In addition to a $0 copay for eligible patients, the program includes free 30-day samples to allow patients to start treatment immediately, as well as a support line for benefit verification and prior authorizations. Additional prior authorization assistance is provided. 

September 6, 2016

The acquisition saw Allergan pay RetroSense Therapeutics a $60 million upfront payment, with the promise of potential regulatory and commercialization milestone payments for the company’s lead development program, RST-001 — a potential therapy for retinitis pigmentosa. 

September 6, 2016
The ads highlight the stories of patients and their loved ones and will run across the country for the next several weeks,
September 6, 2016
The expanded indication for Amgen's biologic was granted by the Food and Drug Administration under accelerated approval. 
 
September 6, 2016

The first set of print and digital ads star Ed, a colon cancer survivor, and other new print ads feature Roxanne, who has lived with heart disease and received a heart transplant.

September 1, 2016

The company also announced a number of other executive-level changes, effective immediately.

August 31, 2016

The U.S. Food and Drug Administration has approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases.

August 31, 2016

Among the changes, the FDA is requiring boxed warnings for nearly 400 products, as well as patient-focused Medication Guides for prescription opioids and benzodiazepines.

August 29, 2016

Afluria Quadrivalent is the second quadrivalent influenza vaccine that Seqirus is offering this season after the FDA approved Flucelvax Quadrivalent in May.

August 25, 2016

Amgen’s Parsabiv is aimed at treating hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.

August 25, 2016

The company has introduced a $300 savings card and increased eligibility for its patient assistance program while continuing to donate EpiPens through its EpiPen4Schools program. 

August 24, 2016

Pfizer will pay $550 million upfront to AstraZeneca upon close of the transaction and a deferred $175 million payment in January 2019 for the development and commercialization rights to five drugs.

August 22, 2016

A preliminary analysis in the study shows that payers might be able to save between $38 million and $63 million per 100,000 members by focusing on patients with three or more overlapping chronic conditions.

August 18, 2016

Among the portfolio’s products are U.S. rights to acne treatment Fabior (tazarotene) foam and plaque psoriasis treatment Sorilux (calcipotriene) foam. 

August 18, 2016

FLUAD was first licensed for use in Italy in 1997. Now approved in more than 30 countries, including the U.S., 81 million doses of FLUAD have been distributed worldwide.

August 17, 2016

The review, published in the American Journal of Managed Care, looked at 26 studies of 27 formulary exclusions, 20 of which looked at the impact that exclusions had on patients. 

August 17, 2016
The death rate from opioid overdose in the United States had increased 200% since the year 2000, with deaths impacting people between ages 25 and 44 years, particularly in southern states. 
August 12, 2016

In addition to Idaho, CVS Pharmacy locations in 30 other states can dispense naloxone to patients without an individual prescription.

August 11, 2016

The Partnership for Health Analytics Research's study looked at predictions for 14 drugs launched since 2012 in various indications. On average, predictions were 11 times higher than the sales reported once the drugs hit the market

August 3, 2016

DSN associate editor David Salazar examines chain pharmacy, including in-depth coverage of pharmacy spending, telehealth, generics and technology, in this multi-page report.

August 3, 2016

A CDC study found that vaccinated people 50 years and older were 57% less likely to be hospitalized from flu than unvaccinated people.

August 3, 2016

Drug Store News caught up with TopRx president Scott Franklin to discuss what’s on the horizon for the national distributor of generic pharmaceuticals.

August 2, 2016

Total spending on products whose patents expired between 2012 and 2015 declined by $14.2 billion last year, according to IMS Health’s Institute for Health Care informatics. And 2016 could bring about further cost reductions.

August 2, 2016

As some companies prepare to market their biosimilars, others are still in development. At the end of 2015, the IMS Institute noted that there were five biosimilars in the pre-registration phase of development.